Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.47 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1804679 | 0.86 | ERN1 (0.56) | ERN1PADI4 | |
| SCHEMBL29952205 | 0.86 | ERN1 (0.56) | ERN1PADI4 | |
| SCHEMBL415661 | 0.82 | ERN1 (0.42) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL30884654 | 0.82 | ERN1 (0.52) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL27188680 | 0.82 | ERN1 (0.52) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL29459661 | 0.80 | ERN1 (0.50) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL1002739 | 0.80 | ERN1 (0.50) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL2252231 | 0.78 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9A | |
| SCHEMBL22445291 | 0.78 | ERN1 (0.41) | ERN1PADI4KDM4EPTGS2RAB9A | |
| SCHEMBL30100079 | 0.78 | ERN1 (0.46) | ERN1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-108610356-B | Benzoxaborole derivatives for the treatment of bacterial infections | 阿纳科制药公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8703742-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2613788-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| CN-103140228-A | Benzoxaborole derivatives for the treatment of bacterial infections | ANACOR PHARMACEUTICALS INC | 2013-06-05 | — | — | CN | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008345-B2 | Boron-containing small molecules | BCL6B, BTD, BROX | ERN1 3162/4885PADI4 2286/4885KDM4E 2938/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | ERN1 3162/4885PADI4 2286/4885KDM4E 2938/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | ERN1 3162/4885PADI4 2286/4885KDM4E 2938/4885 |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | ERN1 3162/4885PADI4 2286/4885KDM4E 2938/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | ERN1 3162/4885PADI4 2286/4885KDM4E 2938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.